Benchmark Upgrades NeoGenomics to Buy, Announces $11 Price Target

Benzinga Newsdesk www.benzinga.com Positive 63.3%

Neg 0% Neu 0% Pos 63.3%

Benchmark analyst Bruce Jackson upgrades NeoGenomics (NASDAQ:NEO) from Hold to Buy and announces $11 price target.

Comments

No comments yet. Be the first!